Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations

Regular aspirin use is associated with reduced risk of colorectal cancer (CRC). Variation in aspirin’s chemoprevention efficacy has been attributed to the presence of single nucleotide polymorphisms (SNPs). We conducted a meta-analysis using two large population-based case-control datasets, the UK-Leeds Colorectal Cancer Study Group and the NIH-Colon Cancer Family Registry, having a combined total of 3325 cases and 2262 controls. The aim was to assess 42 candidate SNPs in 15 genes whose association with colorectal cancer risk was putatively modified by aspirin use, in the literature. Log odds ratios (ORs) and standard errors were estimated for each dataset separately using logistic regression adjusting for age, sex and study site, and dataset-specific results were combined using random effects meta-analysis. Meta-analysis showed association between SNPs rs6983267, rs11694911 and rs2302615 with CRC risk reduction (All P<0.05). Association for SNP rs6983267 in the CCAT2 gene only was noteworthy after multiple test correction (P = 0.001). Site-specific analysis showed association between SNPs rs1799853 and rs2302615 with reduced colon cancer risk only (P = 0.01 and P = 0.004, respectively), however neither reached significance threshold following multiple test correction. Meta-analysis of SNPs rs2070959 and rs1105879 in UGT1A6 gene showed interaction between aspirin use and CRC risk (Pinteraction = 0.01 and 0.02, respectively); stratification by aspirin use showed an association for decreased CRC risk for aspirin users having a wild-type genotype (rs2070959 OR = 0.77, 95% CI = 0.68–0.86; rs1105879 OR = 0.77 95% CI = 0.69–0.86) compared to variant allele cariers. The direction of the interaction however is in contrast to that published in studies on colorectal adenomas. Both SNPs showed potential site-specific interaction with aspirin use and colon cancer risk only (Pinteraction = 0.006 and 0.008, respectively), with the direction of association similar to that observed for CRC. Additionally, they showed interaction between any non-steroidal anti-inflammatory drugs (including aspirin) use and CRC risk (Pinteraction = 0.01 for both). All gene x environment (GxE) interactions however were not significant after multiple test correction. Candidate gene investigation indicated no evidence of GxE interaction between genetic variants in genes involved in aspirin pathways, regular aspirin use and colorectal cancer risk.

[1]  D. Hunter,et al.  Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. , 2005, Journal of the National Cancer Institute.

[2]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[3]  Mathieu Lemire,et al.  Genotype–Environment Interactions in Microsatellite Stable/Microsatellite Instability-Low Colorectal Cancer: Results from a Genome-Wide Association Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[4]  J. Potter,et al.  CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. , 2001, Cancer research.

[5]  G. Casey,et al.  No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. , 2009, World journal of gastroenterology.

[6]  Teruhiko Yoshida,et al.  FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) , 2005, Drug Metabolism and Disposition.

[7]  C. Ulrich,et al.  Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study , 2013, Pharmacogenetics and genomics.

[8]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[9]  R. Minchin,et al.  Expression of monomorphic and polymorphic N-acetyltransferases in human colon. , 1994, Biochemical pharmacology.

[10]  J. Potter,et al.  CYP 2 C 9 and UGT 1 A 6 Genotypes Modulate the Protective Effect of Aspirin on Colon Adenoma Risk 1 , 2001 .

[11]  J. Zell,et al.  Associations of a Polymorphism in the Ornithine Decarboxylase Gene with Colorectal Cancer Survival , 2009, Clinical Cancer Research.

[12]  C. Ulrich,et al.  PTGS2 (COX-2) −765G > C Promoter Variant Reduces Risk of Colorectal Adenoma among Nonusers of Nonsteroidal Anti-inflammatory Drugs , 2005, Cancer Epidemiology Biomarkers & Prevention.

[13]  Julie Goodman,et al.  Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer , 2014, International journal of cancer.

[14]  I. Deary,et al.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 , 2008, Nature Genetics.

[15]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[16]  C. Ulrich,et al.  IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. , 2013, Carcinogenesis.

[17]  Hunter,et al.  Aspirin Use , 8 q 24 Single Nucleotide Polymorphism rs 6983267 , and colorectal cancer According to ctNNB 1 Alterations , 2013 .

[18]  Peter Kraft,et al.  Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. , 2013, Journal of the National Cancer Institute.

[19]  M. A. van de Wiel,et al.  Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism , 2012, Cellular Oncology.

[20]  N. Habermann,et al.  Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[21]  T. Hartman,et al.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions , 2014, Genes, chromosomes & cancer.

[22]  Aung Ko Win,et al.  Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry , 2014, Genes, chromosomes & cancer.

[23]  C. Carlson,et al.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations , 2013, Cancer Causes & Control.

[24]  N Slimani,et al.  Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[25]  Mathieu Lemire,et al.  Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. , 2015, JAMA.

[26]  C. Carlson,et al.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia , 2013, Genes, chromosomes & cancer.

[27]  T. McIntyre,et al.  Intracellular Erythrocyte Platelet-activating Factor Acetylhydrolase I Inactivates Aspirin in Blood* , 2011, The Journal of Biological Chemistry.

[28]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[29]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[30]  Christine Rimorin,et al.  UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin , 2007, Pharmacogenetics and genomics.

[31]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[32]  Jo-Fen Liu,et al.  Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention , 2008, Clinical Cancer Research.

[33]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[34]  Zanke,et al.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 , 2008, Nature Genetics.

[35]  Kebin Liu,et al.  Epigenetics and Colorectal Cancer Pathogenesis , 2013, Cancers.

[36]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[37]  Elizabeth L. Barry,et al.  Variants Downstream of the Ornithine Decarboxylase Gene Influence Risk of Colorectal Adenoma and Aspirin Chemoprevention , 2011, Cancer Prevention Research.

[38]  N. Cook,et al.  Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.

[39]  Junjia,et al.  The effect of UGT 1 A and UGT 2 B polymorphisms on colorectal cancer risk : Haplotype associations and gene-environment interactions , 2022 .

[40]  Aung Ko Win,et al.  Risk of colorectal cancer for carriers of a germline mutation in POLE or POLD1 , 2017, Genetics in Medicine.

[41]  Yin Cao,et al.  Aspirin and colorectal cancer: the promise of precision chemoprevention , 2016, Nature Reviews Cancer.

[42]  R C Garner,et al.  Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. , 2003, Carcinogenesis.

[43]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[44]  B. Simon,et al.  A Gene Expression and Pre-mRNA Splicing Signature That Marks the Adenoma-Adenocarcinoma Progression in Colorectal Cancer , 2014, PloS one.

[45]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[46]  K. Adams,et al.  Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. , 2012, American journal of epidemiology.

[47]  Hong Wang,et al.  Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case–control studies , 2014, Tumor Biology.

[48]  S. Nagar,et al.  Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. , 2004, Pharmacogenetics.

[49]  J. Baron,et al.  Cyclooxygenase-2 Polymorphisms, Aspirin Treatment, and Risk for Colorectal Adenoma Recurrence—Data from a Randomized Clinical Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.